checkAd
    Lineage Cell Therapeutics Aktie
    0,9250
     
    USD
    -4,64 %
    -0,0450 USD
    Letzter Kurs 22:15:00 AMEX
    0,9308
     
    USD
    3.100 STK
    Geldkurs 21:59:59
    0,9310
     
    USD
    1.500 STK
    Briefkurs 21:59:59
    ISIN: US53566P1093 · WKN: A2PP89 · SYM: LCTX · USA

    Neueste Nachrichten

    Lineage to Present at 2024 BIO International Convention
    30.05.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
    21.05.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    09.05.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    OpRegen (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
    06.05.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
    02.05.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
    30.04.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Announces Changes to Board of Directors
    29.04.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
    01.04.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
    18.03.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    RG6501 (OpRegen) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
    13.03.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    RG6501 (OpRegen) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
    11.03.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    07.03.24 · Business Wire (engl.) · Lineage Cell Therapeutics